Hypoxia-Inducible Factor Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Hypoxia-inducible factors (HIFs) are transcription factors that respond to a decrease in available oxygen in the cellular environment or hypoxia. HIF1α expression in hematopoietic stem cells explains the quiescence nature of stem cells for being metabolically maintained at a low rate to preserve the potency of stem cells for long periods in a life cycle of an organism. HIF signaling cascade mediates the effects of hypoxia, the state of low oxygen concentration, on the cell. Hypoxia often keeps cells from differentiating. However, hypoxia promotes the formation of blood vessels and is important for the formation of a vascular system in embryos and tumors. Hypoxia in wounds also promotes the migration of keratinocytes and the restoration of the epithelium. Mechanism of action (MOA) of Hypoxia-Inducible are key oxygen sensors that mediate the ability of the cell to cope with decreased oxygen tension and HIF-1 is among the primary genes involved in the homeostatic process, which can increase vascularization in hypoxic areas such as localized ischemia and tumors. Hypoxia-Inducible Factors are used in the treatment of carcinoma, digestive system diseases, glandular and epithelial neoplasm, lymphoma, adrenal disease, breast diseases, colonic diseases, glioblastoma, liver cancer, and ovarian cancer. Increased prevalence of tumors and blood disorders are the key drivers for the Hypoxia-Inducible Factor market. For instance, according to the World Health Organization 2022, each year, approximately 400,000 children develop cancer. breast and lung cancer are the most prevalent cancers in adults worldwide. Launch of newer products by the market players could seek opportunities that influence extensive research and development in Hypoxia-Inducible Factor. For instance, Merck’s Welireg (Belzutifan) is used to treat tumors. Moreover, the development of novel molecules by key players are coming up to overcome challenges in therapy. For instance, Daiichi Sankyo’s  DS-1093 for the treatment of chronic kidney disease-related anemia is under the various stages of clinical studies.

Key Market Developments:

• In August 2021, Merck’s Welireg (Belzutifan) has received FDA approval for the treatment of patients with certain types of Von Hippel-Lindau (VHL) disease associated tumors.
• In February 2023, GSK’s Jesduvroq (Daprodustat) received FDA approval for the treatment of anemia due to chronic kidney disease.

 Approved Drug Molecules and Brand Names for Hypoxia-Inducible Factor:

• Welireg (Belzutifan)
• Jesduvroq (Daprodustat)

Drugs under the Pipeline for Hypoxia-Inducible Factor:

• Selenomethionine (SLM)
• EP0057
• Tasquinimod (ABR-215050)
• Firtecan Pegol (PEG-SN38)
• Lipotecan (TLC388)
• Tempol (MBM-02)
• EZN-2968
• MK-3795
• GB004
• WP1066
• Simmitecan
• AB521
• APX3330
• DS-1093
• Lipocurc (Liposomal Curcumin)
• ARO-HIF2
• BAY 872243
• PX-478
• Calcium Lactate (OMT-111)
• Everolimus (SVG101)

Clinical Activity and Developments of Hypoxia-Inducible Factor:

As of June 2023, more than 25 companies having approximately 38 molecules targeting the number of cancer diseases. For these molecules, more than hundreds of clinical trials are being conducted and the majority are in phase-2, phase-3 clinical trials by players across the globe. For instance,

• In April 2019, Taiwan Liposome Company completed phase 2, open-label, single-arm, two-stage, multicenter study for evaluating the Efficacy and Safety of Lipotecan (TLC388) as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas.
• In June 2023, GSK completed phase 2, multi-center, placebo-controlled study for evaluating the safety and efficacy of Daprodustat (GSK1278863) versus Placebo in Subjects with peripheral artery disease (PAD).